Development of Robust Cationic Light-Activated Thermosensitive Liposomes: Choosing the Right Lipids
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.3c00602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Puja Gangurde und 6 weiteren Autor:innen. Beteiligte Einrichtung: Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00790 Helsinki, Finla…. Hauptthemen laut MEDLINE: Liposomes, Nanoparticles. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Phospholipid Research Center, Academy of Finland, H2020 European Research Council.
Abstract (Originalsprache)
Extensive research has been conducted on cationic light-activated thermosensitive liposomes (CLTSLs) as a means for site-specific and controlled drug release; however, less attention has been given to the stability of these nanoparticles. Selecting the appropriate lipids is crucial for the development of a stable and responsive system. In this study, we investigated the impact of various lipids on the physical properties of cationic light-activated liposomes. Incorporating poly(ethylene glycol) PEG molecules resulted in uniform liposomes with low polydispersity index, while the addition of unsaturated lipid (DOTAP) resulted in extremely leaky liposomes, with almost 80% release in just 10 min of incubation at body temperature. Conversely, the inclusion of cholesterol in the formulation increased liposome stability too much and decreased their sensitivity to stimuli-responsive release, with only 14% release after 2 min of light exposure. To achieve stable and functional CLTSL, we substituted an equivalent amount of unsaturated lipid with a saturated lipid (DPTAP), resulting in stable liposomes at body temperature that were highly responsive to light, releasing 90% of their content in 10 s of light exposure. We also conducted two atomistic molecular dynamics simulations using lipid compositions with saturated and unsaturated lipids to investigate the effect of lipid composition on the dynamical properties of the liposomal lipid bilayer. Our findings suggest that the nature of lipids used to prepare liposomes significantly affects their properties, especially when the drug loading needs to be stable but triggered drug release properties are required at the same time. Selecting the appropriate lipids in the right amount is therefore essential for the preparation of liposomes with desirable properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00790 Helsinki, Finland.
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland.
- Faculty of Engineering and Natural Sciences, Tampere University, FI-33101 Tampere, Finland.
ORCID-Profile: Puja Gangurde
Förderung
- Phospholipid Research Center
- Academy of Finland
- H2020 European Research Council
Zitieren
APA
Gangurde, P., Mahmoudzadeh, M., Gounani, Z., Koivuniemi, A., Laurén, P., Lajunen, T., & Laaksonen, T. (2023). Development of Robust Cationic Light-Activated Thermosensitive Liposomes: Choosing the Right Lipids. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00602
Vancouver
Gangurde P, Mahmoudzadeh M, Gounani Z, Koivuniemi A, Laurén P, Lajunen T, et al. Development of Robust Cationic Light-Activated Thermosensitive Liposomes: Choosing the Right Lipids. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00602
BibTeX
@article{Gangurde2023,
author = {Gangurde, Puja and Mahmoudzadeh, Mohammad and Gounani, Zahra and Koivuniemi, Artturi and Laurén, Patrick and Lajunen, Tatu and Laaksonen, Timo},
title = {Development of Robust Cationic Light-Activated Thermosensitive Liposomes: Choosing the Right Lipids},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.3c00602}
}
EUVIMED